Literature DB >> 1152674

Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs.

I Valverde, R Dobbs, R H Unger.   

Abstract

Filtration of basal plasma from normal, alloxan-diabetic, and depancreatized dogs on Bio Gel P-10 yielded four glucagon-immunoreactive fractions. One of them appeared in the true glycagon area with the glucagon-125I (3500 mol vt). Of the other three, one appeared in the void volume (greater than 20000 mol wt), another just before the insulin-125I (congruent to 9000 mol wt), and the last one close to the salt peak (less than 2000 mol wt). The increase of total plasma glucagon immunoreactivity observed in depancreatized and alloxan diabetic dogs was mainly due to an increase in the 3500 and 9000 molecular-weight fractions. Arginine infusion in depancreatized dogs caused an increase in the 3500 molecular-weight fraction. Somatostatin or insulin infusion in depancreatized and alloxan-diabetic dogs resulted in disappearance of the 3500 molecular-weight fraction.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1152674     DOI: 10.1016/0026-0495(75)90095-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  32 in total

1.  Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.

Authors:  S F Kuku; J B Jaspan; D S Emmanouel; A Zeidler; A I Katz; A H Rubenstein
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

2.  The role of the liver in glucagon metabolism.

Authors:  J B Jaspan; A H Huen; C G Morley; A R Moossa; A H Rubenstein
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

3.  Enhanced glycemic responsiveness to epinephrine in insulin-dependent diabetes mellitus is the result of the inability to secrete insulin. Augmented insulin secretion normally limits the glycemic, but not the lipolytic or ketogenic, response to epinephrine in humans.

Authors:  M A Berk; W E Clutter; D Skor; S D Shah; R P Gingerich; C A Parvin; P E Cryer
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

4.  Pancreatic glucagon secretion and exocrine function (BT-PABA test) in chronic pancreatitis.

Authors:  U Keller; E Szöllösy; L Varga; K Gyr
Journal:  Dig Dis Sci       Date:  1984-09       Impact factor: 3.199

5.  Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor.

Authors:  S Del Prato; A Rovira; P Tessari; A Avogaro; R Nosadini; I Valverde; R Trevisan; A Tiengo
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

6.  Effect of portasystemic venous shunt surgery on hyperglucagonaemia in cirrhosis: paired studies of pre- and post-shunted subjects.

Authors:  F J Dudley; F P Alford; D J Chisholm; D M Findlay
Journal:  Gut       Date:  1979-10       Impact factor: 23.059

7.  Extrapancreatic glucagon and glucagonlike immunoreactivity in depancreatized dogs. A quantitative assessment of secretion rates and anatomical delineation of sources.

Authors:  W A Muller; L Girardier; J Seydoux; M Berger; A E Renold; M Vranic
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

8.  Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man.

Authors:  J E Liljenquist; G L Mueller; A D Cherrington; U Keller; J M Perry; W W Lacy; D Rabinowitz
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

9.  Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects.

Authors:  J P Palmer; J W Benson; R M Walter; J W Ensinck
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

10.  Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man.

Authors:  S G Rosen; W E Clutter; M A Berk; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.